| Hospice Of Orleans , Inc 14080 West Avenue, Albion, NY, 14411 | |
| (585) 589-0809 |
News Archive
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.
The HHS Biomedical Advanced Research and Development Authority (BARDA) is awarding nine contracts for the advanced research and development of more effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident. The contracts total $35 million for the initial phase and up to $400 million over five years.
An international research team, led from the University of Leeds, has found that a common anti-angina drug could help protect the heart against carbon monoxide poisoning.
The Food and Drug Administration (FDA) on Tuesday approved a new drug called Omontys (peginesatide). This is expected to oust Amgen Inc.'s from its near monopoly in the roughly $6 billion U.S. anemia treatment market.
› Verified 1 days ago
| Name | Hospice Of Orleans , Inc |
|---|---|
| Location | 14080 West Avenue, Albion, New York |
| Hospice ID | 331557 |
| Category | Freestanding Hospice |
| Ownership Type | Voluntary Non-profit - Private |
| Profit Type | NON-PROFIT |
| SSA county code | 550 |
News Archive
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.
The HHS Biomedical Advanced Research and Development Authority (BARDA) is awarding nine contracts for the advanced research and development of more effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident. The contracts total $35 million for the initial phase and up to $400 million over five years.
An international research team, led from the University of Leeds, has found that a common anti-angina drug could help protect the heart against carbon monoxide poisoning.
The Food and Drug Administration (FDA) on Tuesday approved a new drug called Omontys (peginesatide). This is expected to oust Amgen Inc.'s from its near monopoly in the roughly $6 billion U.S. anemia treatment market.
› Verified 1 days ago
| NPI Number | 1780766220 |
| Organization Name | Hospice Of Orleans, Inc. |
| Address | 14080 State Route 31 Albion, New York, 14411 |
| Phone Number | (585)589-0809 |
News Archive
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.
The HHS Biomedical Advanced Research and Development Authority (BARDA) is awarding nine contracts for the advanced research and development of more effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident. The contracts total $35 million for the initial phase and up to $400 million over five years.
An international research team, led from the University of Leeds, has found that a common anti-angina drug could help protect the heart against carbon monoxide poisoning.
The Food and Drug Administration (FDA) on Tuesday approved a new drug called Omontys (peginesatide). This is expected to oust Amgen Inc.'s from its near monopoly in the roughly $6 billion U.S. anemia treatment market.
› Verified 1 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 88.9 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 92.6 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 77.8 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 81.5 | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.
The HHS Biomedical Advanced Research and Development Authority (BARDA) is awarding nine contracts for the advanced research and development of more effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident. The contracts total $35 million for the initial phase and up to $400 million over five years.
An international research team, led from the University of Leeds, has found that a common anti-angina drug could help protect the heart against carbon monoxide poisoning.
The Food and Drug Administration (FDA) on Tuesday approved a new drug called Omontys (peginesatide). This is expected to oust Amgen Inc.'s from its near monopoly in the roughly $6 billion U.S. anemia treatment market.
› Verified 1 days ago
| Home Health Aides | 7.5 |
| Counselors | 0.05 |
| Licensed Practical or Vocational Nurses | 0.5 |
| Medical Social Workers | 1.2 |
| Physicians | 0.25 |
| Registered Nurses | 7.6 |
| Other Personnel | 5 |
| Total Employees | 22.1 |
|---|
News Archive
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.
The HHS Biomedical Advanced Research and Development Authority (BARDA) is awarding nine contracts for the advanced research and development of more effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident. The contracts total $35 million for the initial phase and up to $400 million over five years.
An international research team, led from the University of Leeds, has found that a common anti-angina drug could help protect the heart against carbon monoxide poisoning.
The Food and Drug Administration (FDA) on Tuesday approved a new drug called Omontys (peginesatide). This is expected to oust Amgen Inc.'s from its near monopoly in the roughly $6 billion U.S. anemia treatment market.
› Verified 1 days ago
| Homemakers | 0.5 |
| Others | 3.5 |
| Total Volunteers | 4 |
|---|
News Archive
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.
The HHS Biomedical Advanced Research and Development Authority (BARDA) is awarding nine contracts for the advanced research and development of more effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident. The contracts total $35 million for the initial phase and up to $400 million over five years.
An international research team, led from the University of Leeds, has found that a common anti-angina drug could help protect the heart against carbon monoxide poisoning.
The Food and Drug Administration (FDA) on Tuesday approved a new drug called Omontys (peginesatide). This is expected to oust Amgen Inc.'s from its near monopoly in the roughly $6 billion U.S. anemia treatment market.
› Verified 1 days ago
| Hospice Of Orleans , Inc Location: 14080 West Avenue, Albion, New York, 14411 Phone: (585) 589-0809 |